Ernexa Therapeutics Inc. Business Acquisition, Transaction Costs
Ernexa Therapeutics Inc. (ERNA) had Business Acquisition, Transaction Costs of $250.00 thousand as of 2011-12-31, per its 10-K filed 2013-03-29.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2013-03-29
- 2011-12-31: Business Acquisition, Transaction Costs $250.00K.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2011-12-31 | $250.00K 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |